Showing results (251-260 of 277) with videos related to

Sort By:
Pageof 28
Rhinology|July 1, 2024
COVID-19 olfactory dysfunction: associations between coping, quality of life, and mental healthP T Jacobson, B J Vilarello, C Snyder, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 8, 2019
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trialStephan Ehrhardt, Anton P Porsteinsson, Cynthia A Munro, et al.
Journal of Alzheimer'S Disease : JAD|March 29, 2024
Remote Associations Between Tau and Cortical Amyloid-β Are Stage-DependentSeyed Hani Hojjati, Gloria C Chiang, Tracy A Butler, et al.
NEJM Evidence|August 28, 2023
Computerized Games versus Crosswords Training in Mild Cognitive ImpairmentD P Devanand, Terry E Goldberg, Min Qian, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|May 26, 2024
Subjective versus Psychophysical Measures of Chemosensory Alterations following COVID-19Brandon J Vilarello, Patricia T Jacobson, Clayton J Snyder, et al.
JAMA|December 17, 2025
Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical TrialD P Devanand, Thomas Wisniewski, Qolamreza Razlighi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 4, 2012
Citalopram for agitation in Alzheimer's disease: design and methodsLea T Drye, Zahinoor Ismail, Anton P Porsteinsson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 31, 2021
Patterns of tau pathology identified with 18 F-MK-6240 PET imagingWilliam Charles Kreisl, Patrick J Lao, Aubrey Johnson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 30, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementiaDaniel R Bateman, Sascha Gill, Sophie Hu, et al.
Pageof 28